Sort By
Publication Year
Deposit Date
Title
Type
Access
Publication Year
2018 (2)
2017 (2)
2015 (2)
2014 (2)
2013 (1)
2011 (1)
2010 (1)
Version
M-Rank
M21 (1)
M21a (1)
M22 (2)
M23 (3)

Stokić, Edita

Link to this page

Authority KeyName Variants
871aa108-e854-40e0-9591-516dad5d8aae
  • Stokić, Edita (11)

Author's Bibliography

PCSK9 and Hypercholesterolemia: Therapeutic Approach

Obradović, Milan M.; Zarić, Božidarka; Sudar-Milovanović, Emina; Ilinčić, Branislava; Stokić, Edita; Perović, Milan; Isenović, Esma R.

(2018)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Ilinčić, Branislava
AU  - Stokić, Edita
AU  - Perović, Milan
AU  - Isenović, Esma R.
PY  - 2018
UR  - http://www.eurekaselect.com/158061/article
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/7916
AB  - Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercholesterolemia was made by the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme is responsible for the degradation of the low-density lipoprotein (LDL) receptor (LDLR) found at the surface of the plasma membrane in the liver and directly associated with serum LDL level. Limitations in standard therapy used in the treatment of lipid disorders have led to the development of new drugs, such as an inhibitor of PCSK9. Over the past years, the greatest achievement in discovering the PCSK9 inhibitor was made by designing monoclonal antibodies that disable PCSK9 to bind LDLR and RNA interference to reduce PCSK9 production, but one of the main disadvantages is costeffectiveness. In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.
T2  - Current Drug Targets
T1  - PCSK9 and Hypercholesterolemia: Therapeutic Approach
VL  - 19
IS  - 9
SP  - 1058
EP  - 1067
DO  - 10.2174/1389450119666171205101401
ER  - 
@article{
author = "Obradović, Milan M. and Zarić, Božidarka and Sudar-Milovanović, Emina and Ilinčić, Branislava and Stokić, Edita and Perović, Milan and Isenović, Esma R.",
year = "2018",
url = "http://www.eurekaselect.com/158061/article, http://vinar.vin.bg.ac.rs/handle/123456789/7916",
abstract = "Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercholesterolemia was made by the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme is responsible for the degradation of the low-density lipoprotein (LDL) receptor (LDLR) found at the surface of the plasma membrane in the liver and directly associated with serum LDL level. Limitations in standard therapy used in the treatment of lipid disorders have led to the development of new drugs, such as an inhibitor of PCSK9. Over the past years, the greatest achievement in discovering the PCSK9 inhibitor was made by designing monoclonal antibodies that disable PCSK9 to bind LDLR and RNA interference to reduce PCSK9 production, but one of the main disadvantages is costeffectiveness. In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.",
journal = "Current Drug Targets",
title = "PCSK9 and Hypercholesterolemia: Therapeutic Approach",
volume = "19",
number = "9",
pages = "1058-1067",
doi = "10.2174/1389450119666171205101401"
}
1
4
3
2

Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators

Stokić, Edita; Romani, Andrea; Ilinčić, Branislava; Kupusinac, Aleksandar; Stošić, Zoran; Isenović, Esma R.

(2018)

TY  - JOUR
AU  - Stokić, Edita
AU  - Romani, Andrea
AU  - Ilinčić, Branislava
AU  - Kupusinac, Aleksandar
AU  - Stošić, Zoran
AU  - Isenović, Esma R.
PY  - 2018
UR  - http://www.eurekaselect.com/155079/article
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/7951
AB  - Background: Obesity and micronutrient deficiencies contribute to the risk of cardiometabolic diseases such are type 2 diabetes mellitus and Cardiovascular Disease (CVD). Objective: We examined the frequency of concomitant deficit of Magnesium (Mg) and vitamin D in obese patients and evaluated the connection of these combined deficiencies with indicators of cardiometabolic risk in non-diabetic subjects. Methods: Non-diabetic middle aged adults (n = 80; mean age 36 +/- 4 years, 52% women) were recruited based on weight/adiposity parameters {[}i.e. Body Mass Index (BMI) and body fat percentage (FAT%)]. Cardiometabolic risk indicators {[}insulin resistance (Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)) and CVD risk (Framingham risk score for predicting 10-year CVD)], Mg status (i.e. total serum Mg concentration (TMg), Chronic Latent Mg Deficiency (CLMD) -0.75-0.85 mmol/L), vitamin D status (i.e. serum concentration of 25-hydroxyvitamin D (25(OH) D), vitamin D deficiency < 50 nmol/l) were assessed. Results: Among obese subjects 36% presented a combination of vitamin D deficiency and CLMD. In all studied patients, 25(OH) D and TMg levels both, individually and combined, showed a negative linear correlation with HOMA-IR and CVD risk. In subjects with CLMD (TMg < 0.85 mmol/L), a negative linear coefficient was found between 25(OH) D and, HOMA-IR and CVD risk, compared with subjects with normal TMg status (TMg >= 0.85 mmol/L). Conclusion: CLMD and vitamin D deficiency may commonly be present in obese non-diabetic subjects. Individually and combined, both deficiencies predispose non-diabetic patients to increased risk of cardiometabolic diseases. Maintaining normal Mg status may improve the beneficial effects of vitamin D on cardiometabolic risk indicators.
T2  - Current Vascular Pharmacology
T1  - Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators
VL  - 16
IS  - 6
SP  - 610
EP  - 617
DO  - 10.2174/1570161115666170821154841
ER  - 
@article{
author = "Stokić, Edita and Romani, Andrea and Ilinčić, Branislava and Kupusinac, Aleksandar and Stošić, Zoran and Isenović, Esma R.",
year = "2018",
url = "http://www.eurekaselect.com/155079/article, http://vinar.vin.bg.ac.rs/handle/123456789/7951",
abstract = "Background: Obesity and micronutrient deficiencies contribute to the risk of cardiometabolic diseases such are type 2 diabetes mellitus and Cardiovascular Disease (CVD). Objective: We examined the frequency of concomitant deficit of Magnesium (Mg) and vitamin D in obese patients and evaluated the connection of these combined deficiencies with indicators of cardiometabolic risk in non-diabetic subjects. Methods: Non-diabetic middle aged adults (n = 80; mean age 36 +/- 4 years, 52% women) were recruited based on weight/adiposity parameters {[}i.e. Body Mass Index (BMI) and body fat percentage (FAT%)]. Cardiometabolic risk indicators {[}insulin resistance (Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)) and CVD risk (Framingham risk score for predicting 10-year CVD)], Mg status (i.e. total serum Mg concentration (TMg), Chronic Latent Mg Deficiency (CLMD) -0.75-0.85 mmol/L), vitamin D status (i.e. serum concentration of 25-hydroxyvitamin D (25(OH) D), vitamin D deficiency < 50 nmol/l) were assessed. Results: Among obese subjects 36% presented a combination of vitamin D deficiency and CLMD. In all studied patients, 25(OH) D and TMg levels both, individually and combined, showed a negative linear correlation with HOMA-IR and CVD risk. In subjects with CLMD (TMg < 0.85 mmol/L), a negative linear coefficient was found between 25(OH) D and, HOMA-IR and CVD risk, compared with subjects with normal TMg status (TMg >= 0.85 mmol/L). Conclusion: CLMD and vitamin D deficiency may commonly be present in obese non-diabetic subjects. Individually and combined, both deficiencies predispose non-diabetic patients to increased risk of cardiometabolic diseases. Maintaining normal Mg status may improve the beneficial effects of vitamin D on cardiometabolic risk indicators.",
journal = "Current Vascular Pharmacology",
title = "Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators",
volume = "16",
number = "6",
pages = "610-617",
doi = "10.2174/1570161115666170821154841"
}
4
2
3

Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study

Ilinčić, Branislava; Stokić, Edita; Stošić, Zoran; Kojic, Nevena Eremic; Katsiki, Niki; Mikhailidis, Dimitri P.; Isenović, Esma R.

(2017)

TY  - JOUR
AU  - Ilinčić, Branislava
AU  - Stokić, Edita
AU  - Stošić, Zoran
AU  - Kojic, Nevena Eremic
AU  - Katsiki, Niki
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2017
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1371
AB  - Introduction: Obesity and inadequate vitamin D status are associated with endothelial dysfunction and cardiovascular disease. We evaluated the associations between vitamin D status (i.e. serum levels of 25-hydroxyvitamin D (25(OH)D)), biomarkers of endothelial dysfunction (i.e. serum concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble E-selectin (sE-selectin)), inflammatory markers (i.e. high-sensitivity C-reactive protein (hsCRP) and fibrinogen) and cardiometabolic risk factors. Material and methods: Fifty obese (body mass index (BMI) GT = 30 kg/m(2)) non-diabetic adults (mean age: 36.2 +/- 5.4 years) without pre-existing cardiovascular abnormalities and 25 clinically healthy, normal weight and age matched individuals were included. Anthropometric parameters, markers of glucose and lipid metabolism, and serum levels of inflammatory and endothelial dysfunction biomarkers were assessed in all subjects. Results: The mean serum 25(OH)D level was significantly lower in the obese group than in controls (33.5 +/- 15.2 vs. 60.1 +/- 23.1 nmol/l; p LT 0.001). In the obese group, sE-selectin (36.4 (32.1-47.2) vs. 32.4 (24.6-35.5) ng/ml, p LT 0.05) and hsCRP (6.0 +/- 3.4 vs. 3.5 1.0 mg/l, p LT 0.05) were significantly higher in individuals with lower than median vitamin D levels (i.e. 31 nmol/l) compared with those with higher vitamin D levels. In multivariable linear regression analysis, hsCRP (beta = 0.43; p LT 0.001) and sE-selectin (beta = 0.30; p = 0.03) were independently and significantly associated with serum 25(OH)D levels in the obese group. Conclusions: Vitamin D levels may be related to increased levels of biomarkers of endothelial dysfunction and inflammation in obese non-diabetic individuals.
T2  - Archives of Medical Science
T1  - Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study
VL  - 13
IS  - 1
SP  - 53
EP  - 60
DO  - 10.5114/aoms.2016.61812
ER  - 
@article{
author = "Ilinčić, Branislava and Stokić, Edita and Stošić, Zoran and Kojic, Nevena Eremic and Katsiki, Niki and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2017",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1371",
abstract = "Introduction: Obesity and inadequate vitamin D status are associated with endothelial dysfunction and cardiovascular disease. We evaluated the associations between vitamin D status (i.e. serum levels of 25-hydroxyvitamin D (25(OH)D)), biomarkers of endothelial dysfunction (i.e. serum concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble E-selectin (sE-selectin)), inflammatory markers (i.e. high-sensitivity C-reactive protein (hsCRP) and fibrinogen) and cardiometabolic risk factors. Material and methods: Fifty obese (body mass index (BMI) GT = 30 kg/m(2)) non-diabetic adults (mean age: 36.2 +/- 5.4 years) without pre-existing cardiovascular abnormalities and 25 clinically healthy, normal weight and age matched individuals were included. Anthropometric parameters, markers of glucose and lipid metabolism, and serum levels of inflammatory and endothelial dysfunction biomarkers were assessed in all subjects. Results: The mean serum 25(OH)D level was significantly lower in the obese group than in controls (33.5 +/- 15.2 vs. 60.1 +/- 23.1 nmol/l; p LT 0.001). In the obese group, sE-selectin (36.4 (32.1-47.2) vs. 32.4 (24.6-35.5) ng/ml, p LT 0.05) and hsCRP (6.0 +/- 3.4 vs. 3.5 1.0 mg/l, p LT 0.05) were significantly higher in individuals with lower than median vitamin D levels (i.e. 31 nmol/l) compared with those with higher vitamin D levels. In multivariable linear regression analysis, hsCRP (beta = 0.43; p LT 0.001) and sE-selectin (beta = 0.30; p = 0.03) were independently and significantly associated with serum 25(OH)D levels in the obese group. Conclusions: Vitamin D levels may be related to increased levels of biomarkers of endothelial dysfunction and inflammation in obese non-diabetic individuals.",
journal = "Archives of Medical Science",
title = "Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study",
volume = "13",
number = "1",
pages = "53-60",
doi = "10.5114/aoms.2016.61812"
}
2
12
13
16

Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply)

Stokić, Edita; Kupusinac, Aleksandar; Tomic-Naglic, Dragana; Smiljenic, Dragana; Kovacev-Zavisic, Branka; Srdić-Galić, Biljana; Soskić, Sanja S.; Isenović, Esma R.

(2017)

@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Smiljenic, Dragana and Kovacev-Zavisic, Branka and Srdić-Galić, Biljana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2017",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1589",
journal = "Angiology",
title = "Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply)",
volume = "68",
number = "6",
pages = "561-561",
doi = "10.1177/0003319717691435"
}
1

Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile

Stokić, Edita; Kupusinac, Aleksandar; Tomic-Naglic, Dragana; Zavisic, Branka Kovacev; Mitrovic, Milena; Smiljenic, Dragana; Soskić, Sanja S.; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Tomic-Naglic, Dragana
AU  - Zavisic, Branka Kovacev
AU  - Mitrovic, Milena
AU  - Smiljenic, Dragana
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/395
AB  - Vitamin D deficiency is associated with cardiometabolic risk factors (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We studied 50 obese patients (body mass index [BMI]: 43.5 +/- 9.2 kg/m(2)) and 36 normal weight participants (BMI: 22.6 +/- 1.9 kg/m(2)). The prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D LT 50 nmol/L) was 88% among obese patients and 31% among nonobese individuals; 25(OH)D levels were lower in the obese group (27.3 +/- 13.7 vs 64.6 +/- 21.3 nmol/L; P LT .001). There was a negative correlation between vitamin D level and anthropometric indicators of obesity: BMI (r = -0.64; P LT .001), waist circumference (r = -0.59; P LT .001), and body fat percentage (r = -0.64; P LT .001) as well as with fasting plasma insulin (r = -0.35; P LT .001) and homeostasis model assessment of insulin resistance (r = -0.35; P LT .001). In conclusion, we observed a higher prevalence of vitamin D deficiency among obese participants and this was associated with a proatherogenic cardiometabolic risk profile.
T2  - Angiology
T1  - Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile
VL  - 66
IS  - 3
SP  - 237
EP  - 243
DO  - 10.1177/0003319714528569
ER  - 
@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Zavisic, Branka Kovacev and Mitrovic, Milena and Smiljenic, Dragana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/395",
abstract = "Vitamin D deficiency is associated with cardiometabolic risk factors (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We studied 50 obese patients (body mass index [BMI]: 43.5 +/- 9.2 kg/m(2)) and 36 normal weight participants (BMI: 22.6 +/- 1.9 kg/m(2)). The prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D LT 50 nmol/L) was 88% among obese patients and 31% among nonobese individuals; 25(OH)D levels were lower in the obese group (27.3 +/- 13.7 vs 64.6 +/- 21.3 nmol/L; P LT .001). There was a negative correlation between vitamin D level and anthropometric indicators of obesity: BMI (r = -0.64; P LT .001), waist circumference (r = -0.59; P LT .001), and body fat percentage (r = -0.64; P LT .001) as well as with fasting plasma insulin (r = -0.35; P LT .001) and homeostasis model assessment of insulin resistance (r = -0.35; P LT .001). In conclusion, we observed a higher prevalence of vitamin D deficiency among obese participants and this was associated with a proatherogenic cardiometabolic risk profile.",
journal = "Angiology",
title = "Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile",
volume = "66",
number = "3",
pages = "237-243",
doi = "10.1177/0003319714528569"
}
27
30
29

Vitamin D and Dysfunctional Adipose Tissue in Obesity

Stokić, Edita; Kupusinac, Aleksandar; Tomic-Naglic, Dragana; Smiljenic, Dragana; Kovacev-Zavisic, Branka; Srdić-Galić, Biljana; Soskić, Sanja S.; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Tomic-Naglic, Dragana
AU  - Smiljenic, Dragana
AU  - Kovacev-Zavisic, Branka
AU  - Srdić-Galić, Biljana
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/673
AB  - Vitamin D deficiency and dysfunctional adipose tissue are involved in the development of cardiometabolic disturbances (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We evaluated the relation between vitamin D and adipocytokines derived from adipose tissue. We studied 50 obese individuals who were classified into different subgroups according to medians of observed anthropometric parameters (body mass index, body fat percentage, waist circumference, and trunk fat mass). There was a negative correlation between vitamin D level and leptin and resistin (r = -.61, P LT .01), while a positive association with adiponectin concentrations was found (r = .7, P LT .001). Trend estimation showed that increase in vitamin D level is accompanied by intensive increase in adiponectin concentrations (growth coefficient: 12.13). In conclusion, a positive trend was established between vitamin D and the protective adipocytokine adiponectin. The clinical relevance of this relationship needs to be investigated in larger studies.
T2  - Angiology
T1  - Vitamin D and Dysfunctional Adipose Tissue in Obesity
VL  - 66
IS  - 7
SP  - 613
EP  - 618
DO  - 10.1177/0003319714543512
ER  - 
@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Smiljenic, Dragana and Kovacev-Zavisic, Branka and Srdić-Galić, Biljana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/673",
abstract = "Vitamin D deficiency and dysfunctional adipose tissue are involved in the development of cardiometabolic disturbances (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We evaluated the relation between vitamin D and adipocytokines derived from adipose tissue. We studied 50 obese individuals who were classified into different subgroups according to medians of observed anthropometric parameters (body mass index, body fat percentage, waist circumference, and trunk fat mass). There was a negative correlation between vitamin D level and leptin and resistin (r = -.61, P LT .01), while a positive association with adiponectin concentrations was found (r = .7, P LT .001). Trend estimation showed that increase in vitamin D level is accompanied by intensive increase in adiponectin concentrations (growth coefficient: 12.13). In conclusion, a positive trend was established between vitamin D and the protective adipocytokine adiponectin. The clinical relevance of this relationship needs to be investigated in larger studies.",
journal = "Angiology",
title = "Vitamin D and Dysfunctional Adipose Tissue in Obesity",
volume = "66",
number = "7",
pages = "613-618",
doi = "10.1177/0003319714543512"
}
2
23
23
25

The relationship between vitamin D and obesity

Soskić, Sanja S.; Stokić, Edita; Isenović, Esma R.

(2014)

@article{
author = "Soskić, Sanja S. and Stokić, Edita and Isenović, Esma R.",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/6013",
abstract = "Currently, vitamin D deficiency and obesity are pandemic diseases and they are associated with cardiovascular (CV) disease, metabolic syndrome and type 2 diabetes mellitus (T2DM) and other diseases. Concentrations of 25-hydroxyvitamin D (25(OH) D) (25D) are considered as the best indicator of total body vitamin D stores. An association between reduced circulating 25D concentrations and obesity is well known, but the mechanisms are not totally clear. The role of vitamin D supplementation is still uncertain and prospective interventions will establish its influence, if any, in the treatment of obesity. Vitamin D deficiency is associated with the presence of a cardiometabolic risk profile in the obese. Future trials may establish a role for Vitamin D supplementation in individuals at increased CV risk.",
journal = "Current Medical Research and Opinion",
title = "The relationship between vitamin D and obesity",
volume = "30",
number = "6",
pages = "1197-1199",
doi = "10.1185/03007995.2014.900004"
}
1
22
16
24

Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study

Soskić, Sanja S.; Stokić, Edita; Obradović, Milan M.; Sudar, Emina; Tanić, Nasta; Kupusinac, Aleksandar; Đorđević, Jelena D.; Isenović, Esma R.

(2014)

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Stokić, Edita
AU  - Obradović, Milan M.
AU  - Sudar, Emina
AU  - Tanić, Nasta
AU  - Kupusinac, Aleksandar
AU  - Đorđević, Jelena D.
AU  - Isenović, Esma R.
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/239
AB  - Aim: The aim of this pilot study was to investigate possible associations of LEP promoter polymorphism LEP G-2548A and obesity-associated metabolic and antropometric parameters in obese population. Materials and methods: Group of 31 patients with hyperalimentary type of obesity (mean age: 39.26 +/- 11.45 years; BMI: 41.51 +/- 9.22 kg/m(2)) and 36 healthy, nonobese, normal weight subjects (mean age: 33.55 +/- 6.46 years; BMI: 22.63 +/- 1.94 kg/m(2)) were studied. Blood samples were collected for DNA isolation, serum leptin and serum lipids measurements. LEP G-2548A genotypes were determined by PCR restriction fragment length polymorphism based analyses. Results: No significant differences in genotype and allele frequencies of the LEP G-2548A polymorphism were detected between obese and normal weight subjects. No association was found between this polymorphism and BMI. Obese subjects had statistically significant increase in serum leptin levels compared with control, while no association between leptin concentration and LEP polymorphism LEP G-2548A was found. There is a statistically significant association of LEP G-2548A genotypes with LDL (p LT 0.05), LDL/HDL ratio (p LT 0.001), apoB (p LT 0.01), body weight (p LT 0.001) and waist circumference (p LT 0.001). Conclusion: Our findings indicate that there is an association between LEP G-2548A polymorphism and metabolic and anthropometric parameters in obese patients in a Serbian population.
T2  - Clinical Lipidology
T1  - Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study
VL  - 9
IS  - 5
SP  - 505
EP  - 513
DO  - 10.2217/CLP.14.42
ER  - 
@article{
author = "Soskić, Sanja S. and Stokić, Edita and Obradović, Milan M. and Sudar, Emina and Tanić, Nasta and Kupusinac, Aleksandar and Đorđević, Jelena D. and Isenović, Esma R.",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/239",
abstract = "Aim: The aim of this pilot study was to investigate possible associations of LEP promoter polymorphism LEP G-2548A and obesity-associated metabolic and antropometric parameters in obese population. Materials and methods: Group of 31 patients with hyperalimentary type of obesity (mean age: 39.26 +/- 11.45 years; BMI: 41.51 +/- 9.22 kg/m(2)) and 36 healthy, nonobese, normal weight subjects (mean age: 33.55 +/- 6.46 years; BMI: 22.63 +/- 1.94 kg/m(2)) were studied. Blood samples were collected for DNA isolation, serum leptin and serum lipids measurements. LEP G-2548A genotypes were determined by PCR restriction fragment length polymorphism based analyses. Results: No significant differences in genotype and allele frequencies of the LEP G-2548A polymorphism were detected between obese and normal weight subjects. No association was found between this polymorphism and BMI. Obese subjects had statistically significant increase in serum leptin levels compared with control, while no association between leptin concentration and LEP polymorphism LEP G-2548A was found. There is a statistically significant association of LEP G-2548A genotypes with LDL (p LT 0.05), LDL/HDL ratio (p LT 0.001), apoB (p LT 0.01), body weight (p LT 0.001) and waist circumference (p LT 0.001). Conclusion: Our findings indicate that there is an association between LEP G-2548A polymorphism and metabolic and anthropometric parameters in obese patients in a Serbian population.",
journal = "Clinical Lipidology",
title = "Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study",
volume = "9",
number = "5",
pages = "505-513",
doi = "10.2217/CLP.14.42"
}
1
2

Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk

Stokić, Edita; Kupusinac, Aleksandar; Srdić, Biljana; Tomic-Naglic, D.; Isenović, Esma R.

(2013)

TY  - CONF
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Srdić, Biljana
AU  - Tomic-Naglic, D.
AU  - Isenović, Esma R.
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5740
C3  - Cardiology
T1  - Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk
VL  - 126
SP  - 169
EP  - 169
ER  - 
@conference{
author = "Stokić, Edita and Kupusinac, Aleksandar and Srdić, Biljana and Tomic-Naglic, D. and Isenović, Esma R.",
year = "2013",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5740",
journal = "Cardiology",
title = "Sagittal Abdominal Diameter (Sad) in Identification Obese Patients At Higher Cardiovascular Risk",
volume = "126",
pages = "169-169"
}
1

Peroxisome Proliferator-Activated Receptors and Atherosclerosis

Soskić, Sanja S.; Dobutovic, Branislava D.; Sudar, Emina; Obradović, Milan M.; Nikolić, Dragana; Zarić, Božidarka; Stojanovic, Srdan D.; Stokić, Edita; Mikhailidis, Dimitri P.; Isenović, Esma R.

(2011)

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Dobutovic, Branislava D.
AU  - Sudar, Emina
AU  - Obradović, Milan M.
AU  - Nikolić, Dragana
AU  - Zarić, Božidarka
AU  - Stojanovic, Srdan D.
AU  - Stokić, Edita
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4519
AB  - The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPAR alpha, -gamma, and -delta/beta, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, which might present new approaches involved in the antiatherosclerotic effects revealed in this review. In addition, in this review we are presenting latest data from recent performed clinical studies which have focus on novel approach to PPARs agonists as potential therapeutic agents in the treatment of complex disease such as atherosclerosis.
T2  - Angiology
T1  - Peroxisome Proliferator-Activated Receptors and Atherosclerosis
VL  - 62
IS  - 7
SP  - 523
EP  - 534
DO  - 10.1177/0003319711401012
ER  - 
@article{
author = "Soskić, Sanja S. and Dobutovic, Branislava D. and Sudar, Emina and Obradović, Milan M. and Nikolić, Dragana and Zarić, Božidarka and Stojanovic, Srdan D. and Stokić, Edita and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2011",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4519",
abstract = "The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPAR alpha, -gamma, and -delta/beta, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, which might present new approaches involved in the antiatherosclerotic effects revealed in this review. In addition, in this review we are presenting latest data from recent performed clinical studies which have focus on novel approach to PPARs agonists as potential therapeutic agents in the treatment of complex disease such as atherosclerosis.",
journal = "Angiology",
title = "Peroxisome Proliferator-Activated Receptors and Atherosclerosis",
volume = "62",
number = "7",
pages = "523-534",
doi = "10.1177/0003319711401012"
}
17
22
25

Chronic Hepatitis C, Insulin Resistance and Vascular Disease

Trpković, Andreja; Stokić, Edita; Radak, Đorđe J.; Gluvić, Zoran; Haidara, Mohamed A.; Mikhailidis, Dimitri P.; Isenović, Esma R.

(2010)

@article{
author = "Trpković, Andreja and Stokić, Edita and Radak, Đorđe J. and Gluvić, Zoran and Haidara, Mohamed A. and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2010",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4208",
abstract = "The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.",
journal = "Current Pharmaceutical Design",
title = "Chronic Hepatitis C, Insulin Resistance and Vascular Disease",
volume = "16",
number = "34",
pages = "3823-3829",
doi = "10.2174/138161210794455067"
}
5
3
2